What is Express Diagnostics Int'l?
Express Diagnostics Int'l operates as a critical player in the diagnostic manufacturing landscape, specializing in high-precision drug testing solutions. The company provides a comprehensive suite of products, including urine and saliva-based testing, alcohol screening, and advanced fentanyl harm reduction tools. Beyond its proprietary product line, the firm leverages its U.S.-based manufacturing facilities to offer private labeling and contract manufacturing services. This dual-model approach allows the company to serve as a vital supply chain partner for distributors, ensuring that clients maintain a competitive edge through reliable, research-backed diagnostic technology.
How much funding has Express Diagnostics Int'l raised?
Express Diagnostics Int'l has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Express Diagnostics Int'l
PPP
Public-Private Partnership
What's next for Express Diagnostics Int'l?
With this late-stage capital, Express Diagnostics Int'l is poised to transition into a phase of aggressive market penetration and technological refinement. The strategic focus will likely center on scaling production capacity to meet the rising demand for harm reduction products and expanding its footprint in the clinical diagnostics market. By optimizing its contract manufacturing services, the company aims to deepen its integration with existing distribution partners while exploring new avenues for product innovation. This financial backing provides the necessary runway to solidify its status as a leader in the diagnostic testing industry, ensuring long-term sustainability and operational excellence.
See full Express Diagnostics Int'l company page
